

## Orations –Presentations in Conferences/Symposia

(135 International & National)

S.N.	Topic	Conference	Date/ Year
1	<b>SURGICAL APPROACH TO DIABETIC FOOT ULCERS</b>	IDF 2018 Congress, Hyderabad, Hyderabad,	25 and 27 October 2018
2	LIFESTYLE DISEASES AND POSITIVE HEALTH TALK SHOW BY DR SUDHIR BHANDARI	CME	12-10-2018
3	<b>1ST TOPIC:- NEWER CALCIUM CHANNEL BLOCKER</b> <b>2ND TOPIC:- PECULIAR INFECTIONS IN DIABETES (22-9-2018)</b>	DIACON-2018 (AHMEDABAD)	21-23 <sup>RD</sup> SEP, 2018
4	TOPIC 1ST:- HEART FAILURE & DIABETES-A DEADLY DUO  TOPIC 2ND:- VYMADA-QUALITY OF LIFE (QOL) BENEFITS IN PATIENTS WITH HFREF	CME	18-19 Sep, 2018
5	<b>TOPIC 1ST:- ROLE OF ALPHA CELLS IN DM, A PATIENT CENTRIC APPROACH TO TREATMENT</b> <b>TOPIC 2ND:- GLP1-RA THERAPY: ARE ALL SAME? + RATIONALE TO ADD GLP-1RA TO BASAL INSULIN</b>	DTEECON-2018,Jaipur ( Dr S.K Sharma)	16-9-2018
6	INDIAN PHENOTYPE: NEED FOR EARLY INTENSIFICATION	CME	15 <sup>th</sup> SEPTEMBER,2 018
7	DOES REDUCED PHYSICAL ACTIVITY/EXERCISE INFLUENCE OBESITY RISK ?	AIAAROCON 2018(AURANGABAD)	7-9 <sup>TH</sup> SEP 2018
8	<b>1ST TOPIC:- ROLE OF ALPHA CELLS IN DM, A PATIENT CENTRIC APPROACH TO TREATMENT</b> <b>2ND TOPIC:- DEBATE ON GLP1+BASAL COCKTAIL V/S PREMIX MOCKTAIL ( FOR GLP1+BASAL COCKTAIL)</b>	RSSDI CG STATE CHAPTER, 2018 (RAIPUR)	1-2 <sup>ND</sup> SEP, 2018
9	<b>TOPIC 1ST :- SOCIAL DETERMINANTS OF HEALTH</b> <b>TOPIC 2ND :- OBESITY, OSA AND CARDIOMETABOLIC RISK; IN LONG RUN WHICH IS BEST WEIGHT LOSS OR C PAP?</b>	ACP INDIA CHAPTER CONGRESS-MEDICINE 2018, LUCKNOW	1-9-2018
10	INFLAMMATION AND DIABETES Hydroxychloroquine ( New Therapy in Type II Diabetes Mellitus )	CME	18 <sup>TH</sup> AUG,2018
11	DIABETES & LIFESTYLE DISEASES -THE INDIAN SCENARIO	RAJMAAI CONVENTION 2018, HOUSTON (USA)	9-12 <sup>TH</sup> AUGUST,2018
12	PRAGMETIC APPROACH TO BASAL INSULIN	DIABETES CONCLAVE 2018: MEHSANA (GUJARAT)	29th July, 2018

S.N.	Topic	Conference	Date/ Year
13	SPEAKER:-DIABETES & CVD : EVIDENCES FOR CONTEMPORARY CLASSICS TOPIC :-HYPERGLYCEMIA IN YOUNG ,(MODERATOR) TOPIC :-CHALLENGES IN ACHIEVING ABC GOALS (CHAIRPERSON)	ACADEMIA 2018 , INTERNATIONAL UPDATE,NAGPUR	6-8,July ,2018
14	SAFETY WITH SGLT2I: MYTH VS REALITY	CME	29-6-2018
15	ROLE OF GLUCAGON IN DIABETES	CME	28-6-2018
16	MANAGEMENT OF HYPERGLYCEMIA IN HOSPITALS – ROLE OF INSULIN ANALOG	CME	23-6-2018
17	MANAGING HEART FAILURE IN DIABETES	CME	21-6-2018
18	WELLNESS, FITNESS, AND LIFESTYLE MANAGEMENT CENTRE	CME	18-6-2018
19	HYDROXYCHLOROQUINE NEW THERAPY IN TYPE II DIABETES MELLITUS	CME	16-6-2018
20	LIFESTYLE DISEASES AND POSITIVE HEALTH TALK BY DR SUDHIR BHANDARI	WORLD ICON AWARD BY JITO	9-6-2018
21	MANAGING HEART FAILURE IN DIABETES	Diabetes Update-2018,Kolkata	20-5-2018
22	APPLYING FINDINGS FROM “SPRINT TRIAL IN THE MANAGEMENT OF RENAL DISEASE: DOES A PARTICULAR TYPE OF ANTI-HYPERTENSIVE ADD WEIGHTAGE TO CV PROTECTION OR IS IT ALL ABOUT BP MANAGEMENT	InDEA -2018, Mumbai	19-5-2018
23	LIFESTYLE DISEASES AND POSITIVE HEALTH TALK BY DR SUDHIR BHANDARI	CME	5-5-2018
24	BEHAVIOUR CHANGE FOR LIFESTYLE DISEASES TALK BY DR SUDHIR BHANDARI	CME	23-4-2018
25	INDIAN PHENOTYPE – NEED FOR EARLY INTENSIFICATION	CME	26-4-2018
26	CV Risk Management in Diabetes – Principles and Practices	CME	23-3-2018
27	Treatment after orals: Role of GLP-1RAs in T2DM	CME	23-3-2018
28	Incretin effect and incretin based therapies /Positioning of Incretin based therapy in the treatment Continuum	CME	16-3-2018

S.N.	Topic	Conference	Date/ Year
29	CHOOSING THE RIGHT OPTION IN THE ERA OF PERSONALISATION	CME	10-3-2018
30	CURRENT MANAGEMENT OF OBESITY-LIFESTYLE (DIET, EXERCISE, SYNCHRONIZING CIRCADIAN RHYTHMS ETC.) & INDIAN SYSTEMS	2nd Annual Conference & Symposium on Metabolism and Molecular Medicine in General Practice	10-3-2018
31	C- PEPTIDE MEASUREMENT - A MUST FOR ALL YOUNG DIABETICS	RSSDI Gujarat Chapter-2018	18-3-2018
32	-VENTILATOR ASSOCIATED PNEUMONIA: HOW TO PREVENT AND -ART OF FLUIDS SUSCITATION:RESCUE,OPTIMIZATION, STABILIZATION, AND DE-ESCALATION (ROS- -SIGNIFICANCE OF POSITIVE TROPONIN T IN NON- CARDIAC ICU (	Eternal Criticon 2018 (Chairperson: Dr. Sudhir Bhandari)	24 <sup>th</sup> to 25 <sup>th</sup> Feb, 2018
33	ENDOCRINE MANIFESTATION OF SYSTEMIC DISEASES	APICON 2018	23-2-2018
34	HARNESSING THE POTENTIAL BENEFIT OF HUMAN INSULIN : CLINICAL BENEFITS OF U200 & EVIDENCE	DiabetesIndia 2018	2-2-2018
35	I CARE FOR DIABETES: AN INDIAN CONSENSUS ALGORITHM ON MANAGING T2DM FROM CVD RISK PERSPECTIVE	DiabetesIndia 2018	1-2-2018
36	SGLT-2I AND CARDIO-RENAL EFFECTS	CME	25-1-2017
37	GLP-1 RA THERAPIES – ARE ALL SAME ? & RATIONALE OF ADDING GLP THERAPIES TO BASAL INSULIN	Raj RSSDI-Bikaner	6-1-2017
38	ROLE OF ALPHA CELLS IN DIABETES WITH PATIENT CENTRIC APPROACH OF TREATMENT	CME	30-12-2017
39	THE ROLE OF DPP4 INHIBITOR IN TYPE-2 DIABETES	CME	19-12-2017
40	PRINCIPLES & PRACTICE OXYGEN THERAPY IN ICU,S:	CME	9-12-2017
41	MANAGEMENT OF HEADACHE	API- DIAS-2017	12-11-2017
42	<b>PLENARY SESSION 4</b> <b>SESSION CHAIRMAN:-</b> NEUROSCIENCE RESEARCH IN DISABILITY/EARLY INTERVENTION FOR CHILDHOOD DISORDERS	CME	10-11 <sup>th</sup> Nov- 2017,
43	DIABETES , MUSCLES & BONE DISEASES	Chairing The Session of RSSDI 2017, Bhubaneswar	3 <sup>rd</sup> to 5 <sup>th</sup> Nov, 2017
44	ALL ABOUT SGLT2 INHIBITORS, WHAT IS NEW	RSSDI-Diabetes Update-2017	1-10-2017

S.N.	Topic	Conference	Date/ Year
45	GLOBAL ACADEMIA PRESENTS	CME	27-9-2017
46	GLP1-RA THERAPY: ARE ALL SAME?	CME	20-8-2017
47	PSYCHO-SOCIOLOGY OF DIABETES	API- DIAS-2017	20-8-2017
48	EVIDENCE BASED T2DM MANAGEMENT	CME	16-8-2017
49	NOVEL ROLE OF HYDROXYCHLOROQUIN IN TYPE 2 DIABETES	ACP-2017( India Chapter)	12-8-2017
50	THE FULL PICTURE OF CV SAFETY WITH GLIPTINS: CLINICAL TRIALS AND BEYOND	CME	22-6-2017
51	PREDICT -CARDIOVASCULAR OUTCOMES OF OADS – TOLERABILITY AND BENEFITS WITH SPECIAL REFERENCE TO GLIMEPIRIDE	CME	17-5-2017
52	SGLT2 INHIBITORS FOCUS ON DAPAGLIFLOZIN	CME	6-5-2017
53	"INFLAMMATION & DIABETES-THE LINK" (HYDROXYCHLOROQUINE)	RSSDI-Gujarat 2017	30-4-2017
54	SGLT-2 INHIBITORS- BEYOND THE GLYCEMIC CONTROL	Raj RSSDI 2017	26-3-2017
55	DO WE HAVE ENOUGH EVIDENCES TO USE IN PREGNANCY ?-SU	DIPSI 2017	24-3-2017
56	IN-PATIENT MANAGEMENT OF DIABETES	CME	15-3-2017
57	INCRETIN BASED THERAPY OF TYPE 2 DIABETES MELLITUS	CME	3-3-2017
58	GLYCEMIC VARIABILITY AND THE ROLE OF VOGLIBOSE IN MANAGEMENT OF GV	DIABETESINDIA2017	23- 26 February, 2017
59	TECHNICAL SESSION XII-PHARMOCOGENOMICS OF ANTIDIABETICS	1 <sup>ST</sup> ANNUAL CONFERENCE & SYMPOSIUM ON GENOMICS OF HORMONE & METABOLIC DISORDERS	3 <sup>RD</sup> AND 5 <sup>TH</sup> FEBRUARY 2017
60	DIABETES AND DYSLIPIDEMIA: WHERE DO WE STAND?	CME	9-2-2017
61	WHAT DOES NUMBER MEAN IN MEDICAL PRACTICE	APICON 2017	26-1-2017
62	OPTIMIZING INSULIN INITIATION WORKSHOP	CME	22-1-2017

S.N.	Topic	Conference	Date/ Year
63	LOOKING BEYOND GLYCEMIC CONTROL: SGLT-2 INHIBITORS	CME	12/17/2016
64	NEWER ADVANCES IN MANAGEMENT OF OBESITY	DIACON 2016	3-12-2016
65	HEALTHY LIFESTYLE TO ACHIEVE BETTER QOL IN DIABETES	RSSDI 2016	19-11-2016
66	EMPAGLIFLOZIN: A NEXT GENERATION SGLT2 INHIBITOR?	CME	18-10-2016
67	ALL ABOUT INSULIN THERAPY AND CLINICAL EVIDENCE ON EARLY INSULINISATION AND BIOSIMILAR GLARGINE	CME	7t Oct 2016
68	SGLT2 INHIBITORS FOCUS ON DAPAGLIFLOZIN	CME	30 <sup>th</sup> Sep 2016
69	EVIDENCE BASED T2DM MANAGEMENT	CME	16 <sup>th</sup> Sep 2016
70	BASAL INITIATION AND KNOWLEDGE SHARING (LINKS) INSULIN INITIATION AND OPTIMIZATION STRATEGIES WITH BASAL INSULINS	CME	2 <sup>nd</sup> Sep 2016
71	SGLT2 INHIBITORS FOCUS ON CANAGLIFLOZIN	CME	31 <sup>st</sup> Aug 2016
72	DUAL PPAR ALPHA / GAMMA AGONIST - ROLE IN NASH & DIABETES	<i>American Diabetes Association ADA- PAMS</i>	27 Aug 2016
73	PROLONGING BETA CELL SURVIVAL IN T2DM: MIRAGE OR REALITY?	An Academic initiative by LAI ( <i>Lipid Association of India</i> ) Inner circle meet	13 Aug 2016
74	CHAIRPERSON & KEYNOTE ADDRESS "NON HDL CHOLESTEROL"	CME	12 Aug 2016
75	EVIDENCE BASED T2DM MANAGEMENT	CME	25 <sup>th</sup> June 2016
76	THE ROLE OF DPP4 INHIBITOR IN TYPE-2 DIABETES ARE ALL GLIPTINS WORRY-FREE?	CME	23th April 2016
77	"D DIMER: WHERE TO SEND AND HOW TO INTERPRET"	APICON 2016	28 <sup>th</sup> January 2016
78	HYDROXYCHLOROQUINE NEW THERAPY IN TYPE II DIABETES MELLITUS	IDSII-2016 (International Symposium on Diabetes)	10-1-2016
79	HYPERTENSION IN METABOLIC SYNDROME & IT'S MANAGEMENT	CME	10 <sup>th</sup> & 11 <sup>th</sup> Oct 2015

S.N.	Topic	Conference	Date/ Year
80	INSULIN THERAPY IN DIABETES: WHEN & WHY WHICH & HOW CAN WE EVER OVERCOME CLINICAL PRACTICE BARRIERS?	Raj APICON	2015
81	WHAT DO WE KNOW ABOUT DIABETIC KIDNEY DISEASE FROM OUTCOME TRIALS	ADA (American Diabetes Association) – EASD Combined Sessions	2015
82	PITFALLS OF HYPOGLYCEMIA: GROWING CONCERN IN TODAY'S CLINICAL PRACTICE	ADA (American Diabetes Association) – EASD Combined Sessions	2015
83	TO ASSESS THE EFFECT OF 4MG SAROGLITAZAR ON PATIENTS OF DIABETES DYSLIPIDEMIA WITH NONALCOHOLIC FATTY LIVER DISEASE FOR 24 WEEKS AT DIABETES CARE CENTRE	ADA (American Diabetes Association)	2015
84	INSULIN RESISTANCE, DYSLIPEDEMIA AND PPAR: INDIAN PERSPECTIVE	APICON	2015
85	INDEPENDENT PREDICTORS OF ERECTILE DYSFUNCTION (ED) IN TYPE 2 DIABETES MELLITUS	AACE (American Association of Clinical Endocrinologists)	2015
86	METABOLIC ABNORMALITIES IN PATIENTS TREATED WITH ANTIRETROVIRAL THERAPY	AACE (American Association of Clinical Endocrinologists)	2015
87	PREVALENCE OF GROWTH HORMONE DEFICIENCY IN TYPE 1 DIABETES MELLITUS PATIENTS AT A TERTIARY CARE CENTRE IN INDIA	AACE (American Association of Clinical Endocrinologists)	2015
88	ANALYZING ENDOTHELIAL DYSFUNCTION IN TYPE 2 DIABETES MELLITUS PATIENTS USING FLOW MEDIATED DILATATION SCORE	AACE (American Association of Clinical Endocrinologists)	2015
89	9 MONTH SAFETY AND EFFICACY OF SAROGLITAZAR IN DIABETIC DYSLIPIDEMIA	AACE (American Association of Clinical Endocrinologists)	2015
90	OBESITY AND INSULIN RESISTANCE	All India Association for Advancing Research in Obesity	2014
91	CORRELATION OF METABOLIC SYNDROME WITH IHD (BASED ON CT ANGIOGRAPHY OF CORONARY VESSELS) IN TYPE 2 DIABETES MELLITUS	AACE (American Association of Clinical Endocrinologists)	2014
92	ASSOCIATION OF SERUM INSULIN AND URINARY ALBUMIN WITH OCCULT CAD IN TYPE 2 DIABETES	AACE (American Association of Clinical Endocrinologists)	2014
93	ACUTE BULBAR PALSY A RARE MANIFESTATION OF THYROTOXICOSIS	AACE (American Association of Clinical Endocrinologists)	2014
94	TO STUDY THE ASSOCIATION BETWEEN PLASMA HOMOCYSTEINE AND MICROVASCULAR AND MACROVASCULAR COMPLICATIONS IN TYPE-1 DIABETES MELLITUS	AACE (American Association of Clinical Endocrinologists)	2014
95	GUARD STUDY: EFFECTIVENESS AND SAFETY OF VILDAGLIPTIN AND VILDAGLIPTIN METFORMIN COMBINATION IN INDIAN PATIENTS WITH TYPE 2	EASD (European Association for the Study of Diabetes)	2014

S.N.	Topic	Conference	Date/ Year
	DIABETES MELLITUS		
96	CHROMIUM & DIABETES	Research society for the Study of diabetes in India	2014
97	PERIOPERATIVE MANAGEMENT OF HYPERTENSION	BPCON	2014
98	HOW AGGRESSIVE WE SHOULD BE ADVOCATING SMBG AND FOR WHOM?	Diabetes India, Srinagar	2014
99	TARGETING INSULIN RESISTANCE: FOCUS ON TRIVALENT CHROMIUM	Research society for the Study of diabetes in India	2014
100	ERA OF INDIVIDUALIZING OF DIABETES MANAGEMENT-HAVE INCRETINS PAVED THE WAY!	CME	2013
101	TO STUDY THE ASSOCIATION BETWEEN PLASMA HOMOCYSTEINE AND MICROVASCULAR AND MACROVASCULAR COMPLICATIONS IN TYPE 1 DIABETES MELLITUS	AACE (American Association of Clinical Endocrinologists)	2013
102	GLIPTINS – SAFETY, TOLERABILITY & QUALITY OF LIFE	Diabetes India, Kochi	2013
103	PATHOPHYSIOLOGY OF DIABETES	Diabetes India, Kochi	2013
104	RIGHT TO GOOD HEALTH- DOES POVERTY STAND IN THE WAY?	APICON	2013
105	ASSOCIATION OF SERUM INSULIN AND MICRO ALBUMINURIA WITH OCCULT CORONARY ARTERY DISEASE IN TYPE 2 DIABETES PATIENTS IN NORTH INDIA	IDF (International Diabetes Federation)	2013
106	DIABETIC DYSLIPIDEMIA & ITS MANAGEMENT	CME	2013
107	IS TYPE 2 DM A REALLY CAD EQUIVALENT? HOW TO ASSESS CV RISK IN TYPE 2 DM	Research society for the Study of diabetes in India	2012
108	DIABETES MANAGEMENT – FROM DRIFT TO PARADIGM SHIFT	RSSDI Rajasthan Chapter	2012
109	INCRETIN THERAPIES	CME	2012
110	INCRETIN BASED THERAPY OF TYPE 2 DIABETES MELLITUS	CME	2012
111	SELF-MONITORING OF BLOOD GLUCOSE (SMBG) IN TYPE 2 DIABETES	CME	2011
112	CARDIO FRIENDLY ANTIDIABETICS; NEED OF THE HOUR	CME	2011
113	DRUGS TO TREATMENT IN DIABETIC SEXUAL DYSFUNCTION	Raj Apicon	2011
114	UPDATE ON GLIPTINS : WHAT IS NEW?	RSSDI Rajasthan chapter	2011
115	BETA BLOCKERS: NOT FOR NON-CO-MORBID HYPERTENSION WITH DIABETES	CME	2006
116	OBESITY, DEPRESSION AND CHRONIC MENTAL	APICON	2006

S.N.	Topic	Conference	Date/ Year
	ILLNESS	(The Association of Physicians of India)	
117	BASAL BOLUS: THE STRATEGY FOR MANAGING ALL DIABETES	CME	2006
118	THE ROLE OF DPP4 INHIBITOR IN TYPE-2 DIABETES	APICON (The Association of Physicians of India)	2007
119	INTENSIVE INSULIN THERAPY	CME	2005
120	CCA-IMT (CAROTID INTIMA MEDIA THICKNESS) IN TYPE-2 DIABETES TO PREDICT FUTURE IHD. ITS CO RELATION WITH CTMT AND CORONARY ANGIO GRAPHIC	Raj Apicon at Chitorgardh	2005 Won Dr M. Chenna Reddy Award & Gold Medal for Best scientific Paper
121	RECENT ADVANCES IN MANAGEMENT OF DIABETES	Raj Apicon	2004
122	CCA-IMT (CAROTID INTIMA MEDIA THICKNESS) IN TYPE-2 DIABETES & ITS CO-RELATION WITH RETINOPATHY AND NEPHROPATHY	Raj Apicon at Bikaner	2004 Won Dr M. Chenna Reddy Award & Gold Medal for Best scientific Paper
123	INCIDENCE & MANAGEMENT OF SUB CLINICAL HYPOTHYROIDISM	Raj Apicon at Bikaner	2004
124	PROGNOSTIC SIGNIFICANCE OF MICRO ALBUMINURIA IN DIABETICS & ITS CORRELATION OF VARIOUS COMPLICATION & LIPID PROFILE	APICON (The Association of Physicians of India)	2000
125	RISK FACTOR PROFILE OF CORONARY ARTERY DISEASE: A PILOT STUDY	APICON (The Association of Physicians of India)	2000
126	OBESITY AND CANCER – LETHAL NEXUS		
127	SIGNIFICANCE OF WHR AS A MARKER OF	APICON	1999



S.N.	Topic	Conference	Date/ Year
	IMPAIRED GLUCOSE TOLERANCE TEST	(The Association of Physicians of India)	
128	SIGNIFICANCE OF WHR (WAIST HIP RATIO) IN ASSESSING IMPENDING IGTT	Research society for the Study of diabetes in India, Goa	1995
129	CLINICAL SIGNIFICANCE OF RIGHT SIDED CHEST LEADS IN INFERIOR M.I.	A.P.I. (Association of Physics of India) Jabalpur	1990
130	EFFECT OF DIYOSXR & ISOSORBIDE DITITRATE ON PRE LOAD & AFTER LOAD REDUCTION IN VALVULAR HEART DISEASE – A CLINICAL STUDY	A.P.I. (Association of Physics of India) Calcutta	1989
131	COMPARATIVE EFFORT TOLERANCE OF COMPENSATED VALVULAR HEART DISEASE FOLLOWING DRUG THERAPY OF VASODILATORS & CALCIUM CHANNEL BLOCKERS & BETA BLOCKERS	A.P.I. (Association of Physics of India) Udaipur	1986
132	MANAGEMENT OF PORTAL HYPERTENSION	Indian Society of Gastroenterology	
133	VITAMIN D DEFICIENCY AND CARDIOVASCULAR DISEASES	APICON (The Association of Physicians of India)	
134	DIABETES AND DYSLIPIDEMIA: WHERE DO WE STAND?		
135	DO WE STILL NEED PIOGLITAZONE FOR THE TREATMENT OF TYPE 2 DIABETES?"	Raj Apicon	